Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can tumor markers guide future ovarian cancer treatments?

NCT ID NCT07771400

Knowledge-focused Sponsor: Latin American Cooperative Oncology Group Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 18, 2026 · Last updated Aug 26, 2026 · Updated 3 times

Summary

This study examines tumor samples from 320 Latin American women with advanced ovarian, fallopian tube, or peritoneal cancer to describe the presence of certain markers (FRα, HER2, PD-L1, HRD, and BRCA). Researchers will collect medical history and test archived tumor tissue to see how often these markers overlap. The goal is to better understand the molecular landscape of this cancer in this population, which could inform future treatment strategies.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
This could help identify which patients with advanced ovarian cancer might benefit from targeted therapies based on their tumor's molecular profile.
What could go wrong
This is an observational study, so it won't test treatments directly. Results may not apply to all populations or lead to immediate clinical changes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 320 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Sep 2026

An estimate. Start dates often move.

Expected to finish

Aug 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The study population will consist of 320 participants aged ≥18 years with a diagnosis of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (FIGO stage III-IV), including newly diagnosed, persistent, or recurrent disease, identified between 2018 and 2024 at approximately 16 participating centers across Brazil, Mexico, Colombia, and Argentina. Eligible participants must have histologically confirmed serous, endometrioid, mucinous, or clear cell carcinoma.

Ages

18 years and older

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Participants ≥18 years-old. 2. Patients diagnosed with ovarian, fallopian tube or peritoneal cancer: 1. advanced stages stage III or IV by FIGO disease stage 2. new diagnosis and persistent or recurrent disease 3. Diagnosed from 2018 to 2024. 4. Histologically confirmed diagnosis of serous (low or high grade), endometrioid, mucinous or clear cell ovarian carcinoma. 5. Accept to participate in the project and sign the informed consent (if applicable). 6. An archived representative formalin-fixed paraffin-embedded (FFPE) tumor specimen in tumor tissue blocks (preferred) or freshly sectioned unstained slides (at least 20) from biopsy/surgery is mandatory. Exclusion Criteria: 1. Histological ambiguous diagnosis upon review. 2. Diagnosis based on cytology and without any biopsy or surgical specimen. 3. Patients diagnosed and staged but not receiving any treatment. 4. Patients without medical records available (lost, empty or irretrievable clinical information).

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Fallopian tube cancer stage III are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

fallopian tube cancer fallopian tube neoplasm ovarian cancer ovarian carcinoma peritoneum cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Fallopian tube cancer stage III Fallopian tube cancer stage IV Fallopian tube cancers Ovarian cancer by figo stage Ovarian cancer stage III Ovarian cancer stage IV

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    17 sites in 4 countries. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • ANIMI - Unidade de Tratamento Oncológico

    Lages, Santa Catarina, 88501-001, Brazil

  • CTTB - Centro de Tratamento de Tumores Botafogo (Oncoclínicas)

    Rio de Janeiro, Rio de Janeiro, 22250-905, Brazil

  • Clínica Prognóstica - Centro de Pesquisa Clínica Onconeo

    Campo Grande, Mato Grosso do Sul, 79002-061, Brazil

  • Fundación CTIC - Centro de Tratamiento e Investigación sobre Cáncer

    Bogotá, Colombia

  • Fundación Pita

    Rosario, Argentina

  • Fundação Antonio Prudente - A.C. Camargo Cancer Center

    São Paulo, São Paulo, 01509-001, Brazil

  • Futtura Oncologia Hub de Pesquisa Clinica Ltda

    Porto Alegre, Rio Grande do Sul, 90470-340, Brazil

  • HIAE - Hospital Israelita Albert Einstein

    São Paulo, São Paulo, 05653-000, Brazil

  • Hospital Alemán de Buenos Aires

    Buenos Aires, Argentina

  • Hospital Ángeles Pedregal

    Mexico City, Mexico

  • IMIP - Instituto de Medicina Integral Professor Fernando Figueira

    Recife, Pernambuco, 50070-902, Brazil

  • INCan - Instituto Nacional de Cancerología

    Mexico City, Mexico

  • Instituto Alexander Fleming

    Buenos Aires, Argentina

  • Instituto Nacional de Cancerología Colombia

    Bogotá, Colombia

  • Liga Norte Riograndense Contra o Câncer

    Natal, Rio Grande do Norte, 59062-000, Brazil

  • Oncocentro de Minas Gerais

    Belo Horizonte, Minas Gerais, 30360-680, Brazil

  • TecSalud (Tecnológico de Monterrey)

    Nuevo León, Mexico

More trials for these conditions

Other studies related to the condition(s) this trial covers.